Zepbound Glucagon: In-depth Analysis of Peptide Product Composition
Title: Zepbound Glucagon: In-depth Analysis of Peptide Product Composition Abstract: Zepbound (tirzepatide) integrates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) dual agonism, demonstrating superior glycemic control and weight reduction versus semaglutide (Ozempic/Wegovy). Market trends project the peptide therapeutics sector to exceed $50 billion by 2030, driven by obesity and diabetes prevalence. Compared to single-agonist competitors, Zepbound offers enhanced efficacy but higher gastrointestinal side-effect incidence. Key product parameters include 5–15 mg weekly dosing and 72-hour cold-chain stability. Industry challenges include manufacturing purity (>98% HPLC) and regulatory compliance (FDA/EMA). Selection criteria prioritize supplier GMP certification, batch-specific COAs, and logistics validation for temperature-controlled transport.